Loading...
NPI 1194740571 · Mount Vernon, IL · Family Nurse Practitioner
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Amanda Mckee is a family nurse practitioner provider located in Mount Vernon, Illinois. This profile covers 17 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Amanda Mckee |
| Address | 4121 Veterans Memorial Dr |
| City | Mount Vernon |
| State | IL |
| ZIP | 62864 |
| Taxonomy | Family Nurse Practitioner |
| NPI Enumerated | July 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.5M |
| Medicaid | $1.6M |
This provider’s billing profile is dominated by high-cost, office-administered osteoporosis biologics: J3111 and J0897 together drive the vast majority of drug revenue and the CPT mix (including 99213 and numerous 96372 administrations) is consistent with a clinic organized around frequent injectable treatments rather than a general primary-care panel. The presence of both J3111 (romosozumab) and J0897 (denosumab) as top codes indicates a specialty service line focused on bone-health therapeutics with onsite administration and observation capacity.
Medicare revenue is highly concentrated: the precomputed top three Medicare codes account for 98.5% of this provider’s $5.5M Medicare revenue, led by J3111 ($3.5M, 64.0%) and J0897 ($1.8M, 33.2%), with 99213 contributing $71.1K (1.3%). This concentration means the provider’s Medicare financial performance is tightly tied to continued volume and reimbursement for a very small set of injectable products.
Medicaid revenue shows the same two drugs driving nearly all payment: the top three Medicaid codes account for 98.9% of $1.6M in Medicaid revenue, with J0897 at $825.4K (50.7%) and J3111 at $740.6K (45.5%), and 99213 at $44.7K (2.7%). This mirrored payer pattern indicates the operation’s Medicaid business is also essentially a focused osteoporosis-injection service line rather than broad ambulatory care.
Payer mix is Medicare-weighted: the provider reports $5.5M in Medicare revenue versus $1.6M in Medicaid revenue, so Medicare is the materially larger source of fee-for-service volume and dollars. Analysts should treat Medicare reimbursement trends and access to these specific biologics as primary drivers of near-term revenue risk and opportunity.
On competitive standing, this provider is an outsized national volume leader for the same injectable products: for Medicare J3111 ranks #1 of 970 providers nationally and J0897 ranks #2 of 10057 providers (both 100th percentile; labeled extreme outlier), and even 99213 ranks at the 99th percentile nationally. Those rank/percentile signals identify this clinician as a dominant national-volume participant for these codes rather than a typical local prescriber.
State-level positioning for Medicaid also shows dominance: J0897 ranks #1 of 6 providers in-state (100th percentile; notably above typical state volume) and J3111 is listed as #1 of 1 providers in-state (no peer comparison available). Within Illinois Medicaid this provider appears to be a primary regional supplier of these long-acting osteoporosis injections.
Operational throughput is supported by large administration counts: Medicare shows 96372 with 3.8K claims and $34K revenue (and is noted as an extreme outlier in national ranking), while Medicaid shows 3.1K claims for 96372 with $9.4K revenue. The high counts of 96372 administrations across payers reinforce that injections and associated chair/clinical time are core day-to-day activities, even though the drug codes capture most of the dollars.
The provider has an established NPI history (NPI enumerated on 2006-07-13 (~20 years ago)), which coupled with sustained, concentrated billing for J3111 and J0897 suggests a long-running, specialized infusion/injection practice rather than a new or transient clinic. That tenure supports the interpretation that the observed high volumes reflect deliberate service-line focus and operational capacity built over time.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | 438,270 | $10 | $3.5M |
| J0897 | Injection, denosumab, 1 mg | 101,100 | $20 | $1.8M |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,290 | $60 | $71.1K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 3,780 | $10 | $34K |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,600 | $10 | $20.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 90 | $80 | $7.4K |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 140 | $50 | $6.3K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 60 | $100 | $5.3K |
| 99202 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves straightforward medical decision making, and/or the provider… | 70 | $40 | $2.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 30 | $100 | $2.5K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J3111 | 1 | 30 | 18,010 | $10 | $306.8K |
| J0897 | 1 | 410 | 2,520 | $20 | $90.8K |
| J3304 | 38 | 80 | 1,550 | $10 | $35.6K |
| 99214 | 10,360 | 18,540 | 110 | $80 | $17.1K |
| J7323 | 103 | 140 | 90 | $100 | $13.4K |
| 99213 | 100 | 17,390 | 70 | $60 | $8.8K |
| 20610 | 441 | 1,550 | 60 | $50 | $7.6K |
| 99204 | 5,095 | 8,580 | 30 | $110 | $5.6K |
| 99203 | 3,276 | 6,150 | 30 | $70 | $3.8K |
| 77089 | 16 | 20 | 80 | $30 | $3.6K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | 1,960 | $420 | $825.4K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 1,250 | $590 | $740.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 2,980 | $20 | $44.7K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 3,150 | $1 | $9.4K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 530 | $10 | $6.3K |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 40 | $30 | $1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 20 | $30 | $510 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J3111 | Injection, romosozumab-aqqg, 1 mg | 1 | 10 | 1,250 | $590 | $740.4K |
| J0897 | Injection, denosumab, 1 mg | 1 | 10 | 90 | $530 | $225.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 13,677 | 14,680 | 300 | $50 | $48.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,318 | 14,190 | 280 | $20 | $38.9K |
| 20610 | In this procedure, the provider inserts a needle through the skin of a patient and into a major joint or bursa and then uses the syringe attachment to the needle to remove fluid or he may inject a… | 235 | 320 | 120 | $40 | $14.7K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 643 | 3,330 | 90 | $10 | $7.4K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 26 | 900 | 120 | $10 | $3.5K |
Other providers in the same ZIP code as Amanda Mckee, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.